Keywords
How to Cite
Abstract
The paper presents the results of a survey of 254 patients of reproductive and menopausal age who after the completion of the surgical, in some patients also chemo-radiotherapY., received tamoxifen for breast cancer for different lengths of time. All patients underwent ultrasound examination of pelvic organs and determination of the content of estradiol, follicle-stimulating and luteinizing hormones in the serum. It was showed that with tamoxifen therapy ovarian cysts were diagnosed in 50 women with preserved menstrual cycle (73.5%) and 31 - in menopause (16.6%). Detection of cysts in 72% of patients of reproductive age and 19.3% of menopausal age was accompanied by increased production of estradiol. Cyst formation and hyperproduction of estradiol appeared mainly during the first year of tamoxifen; in the future they could disappear, which made it possible to observe such patients and not immediately made a decision about the need for pharmacological or surgical suppression of ovarian function.References
Aquino N.S., Araujo-Lopes R., Batista I.A. et al. Hypothalamic Effects of Tamoxifen on Oestrogen Regulation of Luteinising Hormone and Prolactin Secretion in Female Rats // J. Neuroendocrinol. - 2016. - Vol. 28. - № 1. - Р. 12338.
Berstein L.M., Wang J.P, Zheng H. et al. Long-term exposure to tamoxifen induces hypersensitivity to estradiol // Clin. Cancer Res. - 2004. - Vol. 10. - № 4. - P. 1530-1534.
Burstein H.J., Lacchetti C., Anderson H. et al. Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression // J. Clin. Oncol. - 2016. - Vol. 34. - № 14. - P. 1689-1701.
Burstein H.J., Temin S., Anderson H. et al. Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update // J. Clin. Oncol. - 2014. - Vol. 32. - № 21. - P. 22552269.
Clarke M. Meta-analyses of adjuvant therapies for women with early breast cancer: the Early Breast Cancer Trialists' Collaborative Group overview // Ann. Oncol. - 2006. - Vol. 17. - P. 59-62.
Cuzick J., Sestak I., Thorat MA. Impact of preventive therapy on the risk of Breast cancer among women with benign Breast disease // Breast. - 2015. - Vol. 24. - S. 2. - P. 51-55.
Dittrich C., Kosty M., Jezdic S. et al. 5ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition//2016. ESMO Open. - 2016. - Vol. 1. - № 5. - P. e000097.
Early Breast Cancer Trialists Collaborative Group (EBCTCG), Davies C, Godwin J, ol. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials // Lancet. - 2011. - Vol. 378. - № 9793. - P. 771-784.
Fisher B., Costantino J.P., Wickerham D.L. et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study // J. Natl. Cancer Inst. - 1998. - Vol. 90. - № 18. - P. 1371-1388.
Han W., Kim H., Ku SY et al. Ovarian cysts during tamoxifen use may affect the prognostic markers of premenopausal breast cancer // Gynecol Endocrinol. - 2013. - Vol. 29. - № 1. - P. 16-19.
Hu R., Hilakivi-Clarke L., Clarke R. Molecular mechanisms of tamoxifen-associated endometrial cancer (Review) // Oncol Lett. - 2015. - Vol. 9. - № 4. - P. 1495-1501.
Jain S., Santa-Maria CA., Gradishar WJ. The Role of Ovarian Suppression in Premenopausal Women With Hormone Receptor-Positive Early-Stage Breast Cancer // Oncology (Williston Park). - 2015. - Vol. 29. - № 7. - Р 473-478.
Jung M., Shin HJ., Rha SY et al. The clinical outcome of chemotherapy-induced amenorrhea in premenopausal young patients with breast cancer with long-term follow-up // Ann. Surg. Oncol. - 2010. - Vol. 17. -№ 12. - P. 3259-3268.
Kedar RP., Bourne TH., Powles TJ. et al. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomized breast cancer prevention trial // Lancet. - 1994. -Vol. 343. - P. 1318-1321.
Kim H.S., Jeon Y.T., Kim Y.B. The effect of adjuvant hormonal therapy on the endometrium and ovary of breast cancer patients // J. Gynecol. Oncol. - 2008. - Vol. 19. - № 4. - P. 256-260.
Madeddu C., Gramignano G., Kotsonis P. et al. Ovarian hyperstimulation in premenopausal women during adjuvant tamoxifen treatment for endocrine-dependent breast cancer: A report of two cases // Oncol Lett. - 2014. - Vol. 3. - P. 1279-1282.
Meirow D., Raanani H., Maman E. et al. Tamoxifen coadministration during controlled ovarian hyperstimulation for in vitro fertilization in breast cancer patients increases the safety of fertility-preservation treatment strategies // Fertil. Steril. - 2014. - Vol. 102. - № 2. - P. 488495.
Metindir J., Aslan S., Bilir G. Ovarian cyst formation in patients using tamoxifen for breast cancer // Jpn. J. Clin. Oncol. - 2005. - Vol. 35. - № 10. - Р 607-611.
Mofrad M.H., Shandiz F.H., Roodsare F.V., Moghiman T. Evaluation of ovarian cysts in breast cancer cases on tamoxifen Asian Pac // J. Cancer Prev. - 2010. - Vol. 11. - № 1. - P 161-164.
Mourits J.E., De Vries E.G.E., Willemse PH.B. et al. Ovarian cysts in women receiving tamoxifen for breast cancer // Br. J. Cancer. - 1999. - Vol. 79. - P. 1761-1764.
Mourits M.J., van der Zee A.G., Willemse P.H. et al. The effects of tamoxifen on the female genital tract // Ned. Tijdschr. Geneeskd. - 2003. - Vol. 147. - № 47. - P. 2315-2320.
Mukai H., Noguchi S., Akiyama F. et al. 2013 clinical practice guidelines (The Japanese Breast Cancer Society): historY., policy and mission // Breast Cancer. - 2015. - Vol. 22. - P. 1-4.
Park W.C. Role of Ovarian Function Suppression in Premenopausal Women with Early Breast Cancer//J. Breast Cancer. - 2016. - Vol. 19. - № 4. - Р 341348.
Phillips K.A., Milne R.L., Rookus M.A. et al. Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers // J. Clin. Oncol. - 2013. - Vol. 31. - № 25. - P. 3091-3099.
Salterberg A. Significance of Ovarian Function Suppression in Endocrine Therapy for Breast Cancer in Pre-Menopausal Women // Geburtshilfe Frauenheilkd. - 2016. - Vol. 5. - P 516-524.
Seoud M., El-Saghir N., Salem Z. et al.Tamoxifen and ovarian cysts: a prospective study // Eur. J. Obstet. Gynecol. Reprod. Biol. - 2001. - Vol. 100. - № 1. - P. 77-80.
Shang Y., Brown M. Molecular determinants for the tissue specificity of SERMs // Science. -2002. - Vol. 295. - P. 2465-2468.
Sherman B.M., Chapler F.K., Crickard K., Wycoff D. Endocrine consequences of continuous antiestrogen therapy with tamoxifen in premenopausal women // J. Clin. Invest. - 1979. - Vol. 64. - № 2. - P. 398-404.
Welsh T.H. Jr, Jia X.C., Jones P.B., et al. Disparate effects of triphenylethylene antiestrogens on estrogen and progestin biosyntheses by cultured rat granulosa cells // Endocrinology. - 1984. -Vol. 115. - № 4. - Р 1275-1282.
Yamazaki R., Inokuchi M., Ishikawa S. et al. Tamoxifen-induced ovarian hyperstimulation during premenopausal hormonal therapy for breast cancer in Japanese women // Springerplus. -2015. - Vol. 4. - P. 425-430.
Zanetto U., Downey G. Benign tumours of the ovary//In: Shaw R., Luesley D., Monga A., editors. Gynecology. 4th ed. Churchill Livingstone: Elsevier. - 2011. - P. 671-672.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2018